PD-1 inhibitors pembrolizumab and nivolumab as well as the PD-L1 inhibitors atezolizumab, avelumab, and durvalumab have all been approved in succession by the Food and Drug Administration (FDA) for treating patients with metastatic NSCLC. Here, CD274 is linked to non-small cell lung carcinoma.